Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000869 | 0.92 | HTR6 (0.78) | HTR6NPC1HTTRAB9AHTR2C | |
| SCHEMBL2003128 | 0.90 | HTR6 (0.80) | HTR6NPC1HTTRAB9AHTR2C | |
| SCHEMBL1876795 | 0.90 | HTR6 (0.80) | HTR6NPC1HTTRAB9AHTR2C | |
| SCHEMBL1028804 | 0.89 | HTR6 (1.00) | HTR6HTR2C | |
| SCHEMBL3147548 | 0.87 | HTR6 (0.85) | HTR6HTR2C | |
| SCHEMBL1575922 | 0.82 | HTR6 (0.87) | HTR6NPC1HTTRAB9AHTR2C | |
| SCHEMBL1576236 | 0.81 | HTR6 (0.74) | HTR6HTR2C | |
| SCHEMBL3157123 | 0.79 | HTR6 (1.00) | HTR6HTR2C | |
| SCHEMBL3144310 | 0.78 | HTR6 (1.00) | HTR6HTR2C | |
| SCHEMBL30244802 | 0.78 | NPC1 (0.66) | HTR6NPC1HTTRAB9AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960568-B2 | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-14 | — | — | US | disclosed |
| US-7960568-B2 | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-14 | — | — | US | disclosed |
| US-7960568-B2 | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-14 | — | — | US | disclosed |
| US-20100076036-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20100076036-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| WO-2008092665-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-07 | — | — | WO | disclosed |
| EP-1953153-A1 | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076036-A1 | HETEROCYCLYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | HTR6, HTR2A, HTR2C | HTR6 1/4885NPC1 2129/4885HTT 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.